Dartmouth researchers have developed a fluorescence imaging technique that can more accurately identify receptors for targeted cancer therapies without a tissue biopsy. They report on their findings in "Quantitative in vivo ...

In a joint effort with the Sunnybrook Research Institute (SRI) in Toronto, Roswell Park Cancer Institute (RPCI) researchers have developed a novel preclinical methodology for examining the effects of neoadjuvant therapy in ...

Exosomes, tiny, virus-sized particles released by cancer cells, can bioengineer micro-RNA (miRNA) molecules resulting in tumor growth. They do so with the help of proteins, such as one named Dicer. New research from The University ...

Treatment with the targeted therapy drug crizotinib effectively halts the growth of lung tumors driven by rearrangements of the ROS1 gene. In an article receiving Online First publication in the New England Journal of Medicine ...

Cancer constantly wages war on the human body. Battles are won, lost or sometimes end in a stalemate. In pancreatic cancer, this stalemate—known as tumor dormancy—can last up to 25 years before becoming aggressively malignant, ...

Transforming growth factor

Transforming growth factor (sometimes referred to as Tumor growth factor, or TGF) is used to describe two classes of polypeptide growth factors, TGFα and TGFβ.

The name "Transforming Growth Factor" is somewhat arbitrary, since the two classes of TGFs are not structurally or genetically related to one another, and they act through different receptor mechanisms. Furthermore, they do not always induce cellular transformation, and are not the only growth factors that induce cellular transformation.